Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Single-arm Clinical Study of Aribulin Combined With Carboplatin and Bevacizumab in the First-line Treatment of Platinum-sensitive Recurrent Ovarian Cancer

NCT05965141 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT05965141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05965141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Single-arm Clinical Study of Aribulin Combined With Carboplatin and Bevacizumab in the First-line Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 1, 2023
Completion date
June 1, 2025
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer